Targeted Molecules in Small Cell Lung Cancer

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 106-111

  Murray, Nevin ^a   Salgia, Ravi ^b   Fossella, Frank V ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTISENSE OLIGONUCLEOTIDE; BB 10901; BCR ABL PROTEIN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; CYSTEINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; FLT3 LIGAND; G PROTEIN COUPLED RECEPTOR; IMATINIB; INTERLEUKIN 3; MAYTANSINE; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P110; PROTEIN P70; PROTEIN P85; PROTEIN SUBUNIT; PROTEIN TYROSINE KINASE; S6 KINASE; STEEL FACTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNINDEXED DRUG; VACCINE;

APOPTOSIS; AUTOCRINE EFFECT; BLOOD TOXICITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE THERAPY; HUMAN; LIVER TOXICITY; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SURVIVAL RATE; TECHNIQUE;

EID: 1242318820     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.021     Document Type: Article

References (20)

1. Page NC, Read WL, Tierney RM, et al: The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 21:305a, 2002 (abstr 1216)
2. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16:1207-1217, 1998
3. Fong KM, Sekido Y, Minna JD: Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 118:1136-1152, 1999
4. Sattler M, Salgia R: Molecular and cellular biology of small cell lung cancer. Semin Oncol 30:57-71, 2003
5. Wang WL, Healy ME, Sattler M, et al: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19:3521-3528, 2000
6. Park GH, Plummer HK III, Krystal GW: Selective Sp1 binding is critical for maximal activity of the human c-kit promoter. Blood 92:4138-4149, 1998
7. Krystal GW, DeBerry CS, Linnekin D, et al: Lck associates with and is activated by Kit in a small cell lung cancer cell line: Inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 58:4660-4666, 1998
8. Arteaga CL, Khuri F, Krystal G, et al: Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol 29:15-26, 2002 (suppl 4)
9. Heinrich MC, Blanke CD, Drucker BJ, et al: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692-1703, 2002
10. Lev S, Blechman JM, Givol D, et al: Steel factor and c-kit protooncogene: Genetic lessons in signal transduction. Crit Rev Oncog 5:141-168, 1994
11. Krystal GW, Honsawek S, Litz J, et al: The selective tyrosine kinase inhibitor ST1571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326, 2000
12. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 18:217-242, 2000
13. Kijima T, Maulik G, Ma PC, et al: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62:6304-6311, 2002
14. Krystal GW, Honsawek S, Kiewlich D, et al: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668, 2001
15. Johnson BE, Fisher B, Fisher T, et al: Phase II study of STI571 (Gleevec) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1171)
16. British Biotech plc: BB-10901 (huN901-DM1) Clinical Investigator's Brochure. (ed 2). England, Oxford, 2002
17. Aletsee-Ufrecht M, Langley K, Rotsch M, et al: NCAM: A surface marker for human small cell lung cancer cells. FEBS Lett 267:295-300, 1990
18. Chari RV, Martell BA, Gross JL, et al: Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131, 1992
19. Liu C, Taddayoni BM, Bourret LA, et al: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 93:8618-8623, 1996
20. Fossella FV, Tolcher A, Elliott M, et al: Phase I trial of the monoclonal antibody conjugate, BB-10901, for relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Proc Am Soc Clin Oncol 21:309a, 2002 (abstr 1232)